WO2008033368A3 - Boroproline compound and cytokine combination therapy - Google Patents

Boroproline compound and cytokine combination therapy Download PDF

Info

Publication number
WO2008033368A3
WO2008033368A3 PCT/US2007/019767 US2007019767W WO2008033368A3 WO 2008033368 A3 WO2008033368 A3 WO 2008033368A3 US 2007019767 W US2007019767 W US 2007019767W WO 2008033368 A3 WO2008033368 A3 WO 2008033368A3
Authority
WO
WIPO (PCT)
Prior art keywords
combination therapy
cytokine combination
boroproline
boroproline compound
compound
Prior art date
Application number
PCT/US2007/019767
Other languages
French (fr)
Other versions
WO2008033368A2 (en
Inventor
Nazneen Aziz
Original Assignee
Nazneen Aziz
Dara Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US84385406P priority Critical
Priority to US60/843,854 priority
Application filed by Nazneen Aziz, Dara Biosciences Inc filed Critical Nazneen Aziz
Publication of WO2008033368A2 publication Critical patent/WO2008033368A2/en
Publication of WO2008033368A3 publication Critical patent/WO2008033368A3/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors

Abstract

A method is provided for treating subjects with boroproline compound and cytokine combination therapy. The invention further provides methods for identifying subjects that are likely to respond to boroproline treatment.
PCT/US2007/019767 2006-09-12 2007-09-12 Boroproline compound and cytokine combination therapy WO2008033368A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US84385406P true 2006-09-12 2006-09-12
US60/843,854 2006-09-12

Publications (2)

Publication Number Publication Date
WO2008033368A2 WO2008033368A2 (en) 2008-03-20
WO2008033368A3 true WO2008033368A3 (en) 2009-05-07

Family

ID=39184306

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/019767 WO2008033368A2 (en) 2006-09-12 2007-09-12 Boroproline compound and cytokine combination therapy

Country Status (1)

Country Link
WO (1) WO2008033368A2 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040077601A1 (en) * 2002-07-09 2004-04-22 Point Therapeutics, Inc. Methods and compositions relating to isoleucine boroproline compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040077601A1 (en) * 2002-07-09 2004-04-22 Point Therapeutics, Inc. Methods and compositions relating to isoleucine boroproline compounds

Also Published As

Publication number Publication date
WO2008033368A2 (en) 2008-03-20

Similar Documents

Publication Publication Date Title
GB2430222B (en) Viscosified treatment fluids and associated methods of use
TWI435729B (en) Methods, compositions, and kits for the treatment of medical conditions
GB2423928B (en) Methods and compositions for treating pain
IL185256A (en) Method and composition for treating peripheral vascular diseases
AU2006231506A8 (en) Device and methods for treating paranasal sinus conditions
EP1813218A4 (en) Ultrasonic treating device, endoscope device and treating method
EP1968607A4 (en) Treatment of cancer and other diseases
EP2231276A4 (en) Methods and devices for orthovoltage ocular radiotherapy and treatment planning
EP1755733A4 (en) Methods and devices for thermal treatment
EP2382010A4 (en) Methods and systems for fat reduction and/or cellulite treatment
IL181304D0 (en) Dihydropteridinones for the treatment of cancer diseases
WO2010059839A3 (en) Method of treating sleep disordered breathing
TWI466929B (en) Polysilazane treatment solvent and method for treating polysilazane using the same
EP2091454A4 (en) Apparatus and method for skin treatment
EP1727498A4 (en) Endovascular treatment devices and methods
EP2079500A4 (en) Infusion devices and methods
EP1742590A4 (en) Device and method for treating tissue
GB0701576D0 (en) Porous composites containing hydrocarbon-soluble well treatment agents and methods for using the same
SI2443246T1 (en) Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
IL181895D0 (en) System and method for variable depth ultrasound treatment
EP1737482A4 (en) Compositions and methods for treating diseases
EP1901694A4 (en) Method and apparatus for the treatment of tissue
WO2008048471A3 (en) Obstructive sleep apnea treatment devices, systems and methods
EP2125855A4 (en) Methods and compositions for the treatment of cancer or other diseases
EP1742641A4 (en) Methods and compositions for detecting and treating retinal diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07838048

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07838048

Country of ref document: EP

Kind code of ref document: A2